Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04953780 · ClinicalTrials.gov registry record · Phase 1

2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML

A Phase 1 study of Acute Myeloid Leukemia, sponsored by West Virginia University.

Active
Registry status
Phase 1
Development phase
6
Enrollment target
2
Study locations

NCT04953780 is a Phase 1 study of Acute Myeloid Leukemia that is active but no longer recruiting, run by West Virginia University. The registered enrollment target is 6 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04953780, a Phase 1 study of Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by West Virginia University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
2
Study locations

Study Summary

Characterizing the regimen limiting toxicity (RLT) of chemotherapeutic drug Calaspargase Pegol-mknl as remission induction and consolidation chemotherapy in patients with newly diagnosed Acute Myeloid Leukemia (AML) and Identifying the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Calaspargase Pegol-mknl.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG Calaspargase pegol-mknl

Study Locations (2)

Maryland

  • Greenebaum Cancer Center, University of Maryland Medical Systems - Baltimore

West Virginia

  • West Virginia University - Morgantown

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2021-09-27
Est. Completion 2025-12-31
Phase Phase 1

Sponsor

West Virginia University

122 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04953780

The ClinicalTrials.gov registry entry for NCT04953780 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (95% lower). The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Calaspargase pegol-mknl is the first listed.

NCT04953780 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, West Virginia.

Frequently Asked Questions

What is clinical trial NCT04953780 about?

NCT04953780 is a clinical study titled "2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML". Characterizing the regimen limiting toxicity (RLT) of chemotherapeutic drug Calaspargase Pegol-mknl as remission induction and consolidation chemotherapy in patients with newly diagnosed Acute Myeloid Leukemia (AML) and Identifying the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)...

What is the current status of trial NCT04953780?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-09-27. Estimated completion is 2025-12-31.

What conditions does trial NCT04953780 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT04953780?

The interventions under investigation include: Calaspargase pegol-mknl (DRUG).

Who is sponsoring clinical trial NCT04953780?

This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04953780 being conducted?

This trial has 2 study locations across Maryland, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.